Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 

    We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

     

    Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Currently, we do not have any studies available for those diagnosed with liver impairment. We hope to start a study in the near future. 

    Contact Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1321 Cohort 9: Healthy Male and Female Volunteers

    Study 1321: Healthy Participants

    Research Purpose:  Study 1321 is designed to evaluate an investigational drug being developed for the treatment of certain inflammatory disorders. The purpose of the study is to evaluate the absorption/elimination rate and safety/tolerability of the study drug.  

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Age 18-55 years
    • Body Mass Index (BMI) between 18-32 kg/m²
    • Must be healthy; not being evaluated or treated for any medical conditions.
    • Cannot take medications on a regular basis (Exception: women can be using a prescribed hormonal birth control)
    • No history of cancer (Exception: cured basal or squamous cell skin cancers)
    • No history of drug addiction or alcoholism 12 months prior to the screening appointment
    • No use of more than the equivalent of 5 cigarettes per week in the two months before the screening appointment.
    • Must be able and willing to refrain from use of tobacco or nicotine containing products one week before the study starts until the end of the study
    • Must be able and willing to eat/drink a study specific meal which includes pork, eggs, dairy, and gluten.

    Study Time Commitment: Study participation will last for approximately 3 ½ weeks.

    Inpatient stay

    Three short inpatient stays lasting approximately 72 hours (three overnights) each time. The inpatient stays will be separated by one week

    Outpatient Visit

    There will be one brief outpatient visit following the final inpatient stay.

    Screens start: 8/15/17

    Study Dates start: 9/11/17

    Compensation: up to $2550 for participation time 

    For information contact Dayna 651-724-5047 or email: daynas@prismresearchinc.com

  • 1613 Part2: Healthy Males and Females

    Study 1613 Part 2: Healthy Female and Male Participants

     

    Research Purpose: To evaluate the safety and tolerability of an investigational drug being developed for the treatment of peanut allergy.

     *September Dates*

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women on hormonal birth control are allowed to participate provided they use an approved secondary method of birth control.

    Age

    18-45 years

    Weight/Body Mass Index (BMI)

    Weight between 88 – 198 lbs. for women and between 110 – 220 lbs. for men. 

    BMI between 18-30 kg/m²

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes more frequently than 5 cigarettes per day prior to the study is allowed.  No tobacco/nicotine use is permitted for the duration of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

     

     

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks with 2 follow-up phone questionnaires 6 months apart.

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in Clinic stay will last approximately 9 days (8 overnights)

    Outpatient Visits

    • There are 21 clinic visits following the discharge from the clinic.
    • End of study will be Day 35.
    • There will be 2 follow-up telephone questionnaires that will be performed approximately 6 months apart after completion of the clinic visits.

     

     

    Compensation for participation time: Up to $4695.00

     

    For information regarding this study contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

  • Study 1710 Part 1: Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at last a month prior to screening

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 11 weeks. 

    Clinic Stay

    • Participants will be confined at Prism Clinical Research one time during the study period for up to 16 days and (15 nights).

    Return Clinic Visits

    • There is one return clinic visit approximately 1 week after discharge.

     

    Phone Call

    • There is one Phone call approximately 30 days after your final return visit.

     

    Screenings begin: July 19th 2017

    Anticipated start date for Study 1710:  25 July 2017            

     

    Compensation for participation time: Up to $3725.00 if all clinic visits are completed.

                           

    For information regarding this study contact Kevin @: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Study 1715: Healthy Males and Females

    Study 1715: Healthy Male and Female Participants

     

     

    Research Purpose: Research study 1715 is designed to evaluate an investigational drug being developed for the treatment of migraine. Participants will receive the investigational drug in the form of a sub-cutaneous dose with an injection device to evaluate two dosing methods as well as the general safety/tolerability of the investigational drug how quickly the body process and eliminates the investigational drug.

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Use of non-horminal birth control is required; hormonal birth control is not allowed.

    Age

    18 - 55 years of age

    Body Mass Index (BMI)

    Between 18-30 kg/m²

    Tobacco/Nicotine Use

    No more than the equivalent of 10 cigarettes/day in the 30 days prior to the start of the study and through the duration of the study.

    Alcohol/Drug Abuse History

    History of drug or alcohol abuse within 1 year before the start of the study.Must test negative for drugs of abuse before the start of the study.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case-by-case basis by the study doctor.  Any history of psychiatric illness such as anxiety, depression, or schizophrenic is not allowed.

    Restricted Medications

    Hormonal birth control is not allowed.  No regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements within 30 days prior to the start of the study unless approved by the study doctor.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 17 weeks, including screening.

     

    Clinic Stay

    • Participants will be confined at Prism Clinical Research one time during the study.
    • The in Clinic stay will last approximately 36 hours (1 overnight stay)

    Return Clinic Visits

    • There are 20 brief clinic visits following the in Clinic stay (approximately 1 hour each).

     

     

    Screenings begin: 08/10/2017

    Anticipated start date for Study : 08/14/2017 

     

    Compensation for participation time: Up to $2200.00 if all clinic visits are completed.

                           

    For information regarding this study contact Lindsay: at 651-368-3360 

    lindsayd@prismresearchinc.com or

     Dayna: 651-724-5047, daynas@prismresearchinc.com 

     

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements

    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits

    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

Recent News

  • New Clinical Research Consortium Provides Integrated Development Platform in Medical Alley

    Prism Research is one of 5 leading Minnesota based research organizations that have partnered to provide the most comprehensive clinical development platform in the industry. To find out more, click the link below.

    http://bit.ly/2p040od

  • 7- Signs of Liver Problems

    Prism is now conducting studies for volunteers with liver impairment. Quick- read- article to address 7 signs of a bad liver condition. 

    http://bit.ly/2qvYpnr

     

  • DaVita Clinical Research and Prism Clinical Research choose Verified Clinical Trials to prevent duplicate enrollment in clinical trials

    MINNEAPOLIS (Jan. 17, 2017) – DaVita Clinical Research (DCR), a specialty contract research organization with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a leader in providing fully integrated clinical research services to pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials. 

     

    Simultaneously enrolling in multiple clinical trials, or duplicate enrollment, has become a serious problem in the clinical research world. A growing number of research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse. This creates dangerous issues for the drug manufacturer, the research site, the data quality, and, most importantly, the volunteer.

     

    “We are pleased to have these two clinical research leaders join out network,” said Dr. Mitchell Efros, CEO of VCT. “Our system will allow both companies to take big steps forward in preventing duplicate enrollment and the risks associated.”

     

    VCT maintains a global clinical trial research subject database registry to counter attempts at duplicate enrollment in clinical trial research. The majority of phase I units and an increasingly large number of late phase sites in North America use Verified Clinical Trials, making VCT by far the largest North American clinical research subject database registry in both early and late phase clinical trials.

     

    “DCR is passionate about ensuring data quality and research subject safety,” said Amy Young, vice president and general manager of DCR. “Partnering with Prism and using the VCT system is the right thing to do for all our stakeholders.”

     

    Experts and leaders in the field of hepato-renal clinical trials, Prism and DCR join a vast network of research sites and pharmaceutical companies in their efforts to prevent duplicate enrollment and other important protocol violations in clinical trials.

     

    ”Prism is glad to be participating in this joint effort with our research neighbor, DCR,” said Jeff Cosgrove, president of Prism Research. “We’ve always been proactive in combating dual enrollment, but VCT gives us state-of-the-art technology and processes toward that end.”

     

    Located in close proximity to the Minneapolis and St. Paul metropolitan area, Prism and DCR specialize in early phase clinical research in healthy volunteer trials and many patient-based volunteer trials, including those in hepatic and renal insufficiency populations.

     

     

    About Prism Clinical Research

    Prism Clinical Research is a Twin Cities–based clinical research company committed to the advancement of improved medical knowledge and the community’s health. Since 2005, Prism has provided FDA-approved, investigational pharmaceutical and medical device testing services on behalf of drug and device manufacturers, academic and private physicians, as well as other researchers across Minnesota.

     

    About DaVita Clinical Research

    DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR’s Early Clinical Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase IIb through post-marketing) network of physicians and investigative sites, and Real World Healthcare Data are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit http://www.davitaclinicalresearch.com.

     

    About Verified Clinical Trials

    Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials halts duplicate enrollment in clinical trials and defines itself as the world’s leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials, and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value-added services to the clinical research site, CRO, and Pharmaceutical Sponsor that prove invaluable with regards to financial and legal issues and liabilities. Verified Clinical Trials prevents several other key protocol deviations. For more information, RSVP to or visit

    http://www.verifiedclinicaltrials.com.

  • BMI 101: What's in a number?

    BMI stands for "Body Mass Index," and it's a calculation determined by your heigh and weight. There is almost always a BMI range in Prism's studies. And, let's be honest, for many of us that range can be a tight fit.

    Why does the BMI range exist? To provide an expected norm within which the population of participants will fall.

    Why is there a BMI limit? A participant with a higher BMI may require a greater dose of the study drug and therefore may metabolize the drug differently than a person with a lower BMI.

    Why does the BMI range change from study to study? The range is determined by the study sponsor - the company paying Prism Research to conduct the study. The range is based on the type of study, the procedures being done, and the study drug.

  • Prism Rides "Tour de Cure"

    Tour de Cure

    Prism staff took part in the American Diabetes Association's "Tour de Cure" June 1st. Our ride wasn't the end of our organization's efforts to stop diabetes. We're advancing diabetes research right here in St. Paul!

    If you or a loved one suffers from diabetes, consider telling them about Prism's continued commitment to offer studies for diabetics.

  • OmniComm Systems, Inc. Celebrates Innovation and Excellence at Third Annual Innovation Forum

    Prism Research receives Innvovation and Excellence Award! http://www.omnicomm.com/press/2013_11_22__OmniComm_Systems_Celebrates_Innovation_and_Excellence_at_Third_Annual_Innovation_Forum.html

  • Our Hometown -The Twin Cities

    We love being a part of the Twin Cities metro for so many reasons.  Great food, great lakes, but most importantly great volunteers and people.  Below is a link to why hometown foodie Andrew Zimmern loves the Twin Cities!

    http://andrewzimmern.com/2013/08/27/my-hometown/?sf17040496=1

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel